Nuclide Tongchuang Chongqing
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nuclide Tongchuang Chongqing - overview
Established
2022
Location
Chongqing, -, China
Primary Industry
Healthcare
About
Established in 2022 and based in Chongqing, China, State Power Investment Corporation Nuclide Tongchuang (Chongqing) Technology Co. , Ltd, trading under the name Nuclide Tongchuang Chongqing, focuses on isotope production and nuclear technology innovation. In October 2025, the company closed a round of series A funding to accelerate the construction of its Chongqing Medical Isotope Project (Phase I). The company provides a range of products and services related to isotope manufacturing, nuclear technology development and medical equipment operations.
The company generates revenue primarily through the production and sale of radioactive isotopes, medical devices and nuclear measuring instruments. The company plans to use the series A funding to accelerate the completion and commissioning of its Chongqing Medical Isotope Project (Phase I) and enhance domestic capabilities in the R&D and production of medical isotopes.
Current Investors
China Asset Management, Neovision Capital, SPIC Industrial Fund Management
Primary Industry
Healthcare
Sub Industries
Healthcare, Medical Devices & Equipment, Pharmaceuticals
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.